These updates includes material published by third parties and compiled by PAHO. PAHO has taken reasonable precautions to verify the information contained in the document. However, this material is being distributed without warranty of any kind. The reader is responsible for the interpretation and use of this information and in no event shall PAHO be held liable for any damages arising from its use.
  • Updates
  • Clarifications/conclusions of events presented in previous communications
  • Other related updates

ANVISA requests modification of Oxford-AstraZeneca-Fiocruz vaccine package insert

On Wednesday, 4 April 2021, ANVISA reported that it had requested modification of the insert for the Oxford- AstraZeneca-Fiocruz vaccine, to include in the warnings and precautions section the possibility of very rare cases of blood clots associated with thrombocytopenia.

Read more

Possible explanation of rare prothrombotic events with the AstraZeneca vaccine in Europe

There are press releases and communiqués, though no published studies, stating the following: In response to reports that emerged after a few recipients of the AstraZeneca COVID-19 vaccine...

Read more

GACVS statement on rare thrombotic events with the AstraZeneca vaccine in Europe

The COVID-19 subcommittee of the Global Advisory Committee on Vaccine Safety (GACVS) met in March 2021 to review available data on cases of thromboembolism and thrombocytopenia reported following administration of the AstraZeneca COVID-19 vaccine.

Read more